Literature DB >> 2457353

Possible neurotransmitter basis of behavioral changes in Alzheimer's disease.

A M Palmer1, G C Stratmann, A W Procter, D M Bowen.   

Abstract

Serotonin, 5-hydroxyindoleacetic acid, and homovanillic acid concentrations have been determined in 10 areas of the cerebral cortex from 17 subjects with Alzheimer's disease and 18 control subjects. The dopamine metabolite was not reduced in any area, whereas both indoleamines were reduced in the superior frontal, inferior temporal, and fusiform gyri, and the temporal pole. These areas and areas of the parietal cortex, where there were no changes in concentration, have not previously been reported on. We argue that the large loss of indoleamines from the frontal lobe (to 50-63% of control values) is rather unexpected based on other biochemical measurements and may relate to behavioral changes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457353     DOI: 10.1002/ana.410230616

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  31 in total

1.  Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms.

Authors:  A W Procter; P T Francis; G C Stratmann; D M Bowen
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

2.  Treatment of Alzheimer's disease.

Authors:  D M Bowen; P T Francis; A W Procter; A B Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-04       Impact factor: 10.154

3.  Gene-environment interplay in affect and dementia: emotional modulation of cognitive expression in personal outcomes.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

4.  Can gabapentin be a safe alternative to hormonal therapy in the treatment of inappropriate sexual behavior in demented patients?

Authors:  Chadi Alkhalil; Nillay Hahar; Bachar Alkhalil; George Zavros; David T Lowenthal
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

5.  Molecular imaging of serotonin degeneration in mild cognitive impairment.

Authors:  Gwenn S Smith; Frederick S Barrett; Jin Hui Joo; Najlla Nassery; Alena Savonenko; Devin J Sodums; Christopher M Marano; Cynthia A Munro; Jason Brandt; Michael A Kraut; Yun Zhou; Dean F Wong; Clifford I Workman
Journal:  Neurobiol Dis       Date:  2017-05-13       Impact factor: 5.996

Review 6.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 7.  Monoamine neurons in aging and Alzheimer's disease.

Authors:  A M Palmer; S T DeKosky
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  Combined treatment with a 5HT1A receptor agonist and a muscarinic acetylcholine receptor antagonist disrupts water maze navigation behavior.

Authors:  M Riekkinen; J Sirviö; T Toivanen; P Riekkinen
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

9.  Disruptive behavior as a predictor in Alzheimer disease.

Authors:  Nikolaos Scarmeas; Jason Brandt; Deborah Blacker; Marilyn Albert; Georgios Hadjigeorgiou; Bruno Dubois; Davangere Devanand; Lawrence Honig; Yaakov Stern
Journal:  Arch Neurol       Date:  2007-12

10.  Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy.

Authors:  D M Bowen; A W Procter; D M A Mann; J S Snowden; M M Esiri; D Neary; P T Francis
Journal:  Psychopharmacology (Berl)       Date:  2007-11-18       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.